Oct 29, 2025 6:20 AM Eastern Daylight Time GE HealthCare reports third quarter 2025 financial results Share CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We delivered robust orders with growth across all segments in the third quarter. This was led by customer demand for our differentiated solutions and a healthy capital equipment environment. Revenue performance was ...

Core Insights - GE HealthCare Technologies Inc. (GEHC) has received the CE mark for its Carevance patient monitor, which is expected to enhance accessible and reliable care for customers in Europe [1][11] - Carevance expands GE HealthCare's modular monitoring solutions portfolio, aiming to provide a unified monitoring solution adaptable to various patient needs [2][6] - The regulatory clearance is anticipated to significantly bolster GE HealthCare's Monitoring Solutions business and strengthen its market position [3][9] Company Performance - Following the announcement of the CE mark, GE HealthCare's shares increased by nearly 0.8% [4] - The company currently has a market capitalization of $34.74 billion and an earnings yield of 5.9%, outperforming the industry's negative yield [5] - In the last reported quarter, GE HealthCare achieved an earnings surprise of 16.5% [5] Product Significance - Carevance is designed to provide clinically reliable and cost-effective monitoring solutions, addressing challenges such as staffing shortages and increasing patient complexity [6][11] - The new Cardiac Output Insights feature in Carevance allows for advanced hemodynamic monitoring without the need for additional hardware or invasive procedures [7] Industry Prospects - The global cardiac output monitoring device market is projected to grow from $3.11 billion in 2024 to $5 billion by 2035, with a CAGR of approximately 4.4% [8] - Factors driving this growth include the adoption of advanced monitoring technologies and the acceptance of less invasive procedures [8] Recent Developments - GE HealthCare has announced collaborations with The Queen's Health Systems and Duke Health to advance AI-driven hospital operations software [10] - The company also launched CareIntellect for Perinatal and unveiled the Carestation 850 anesthesia delivery system [12]

Core Insights - GE HealthCare Technologies Inc. (GEHC) launched CareIntellect for Perinatal, a cloud-first Software-as-a-Service (SaaS) application aimed at enhancing maternal and fetal care through actionable insights [1][10] - The launch is expected to strengthen GE HealthCare's Patient Care Solutions (PCS) business and solidify its position in the perinatal care market [2][10] Company Developments - The CareIntellect for Perinatal application was developed in collaboration with HCA Healthcare, integrating various clinical data sources to facilitate clinician workflows and improve patient monitoring [5][6] - GE HealthCare's market capitalization stands at $33.03 billion, with an earnings yield of 6.3% and a recent earnings surprise of 16.5% [4] Market Trends - The global clinical perinatal software market is projected to grow from an estimated $169.9 million in 2024 at a CAGR of 10.3%, driven by increasing birth rates and the need for improved obstetric care [7][8] - Following the announcement of the new product, GE HealthCare's shares increased by nearly 0.7%, reflecting positive market sentiment [3] Recent Product Launches - In addition to CareIntellect for Perinatal, GE HealthCare recently unveiled Carestation 850, a next-generation anesthesia delivery system [9]